Prosecution Insights
Prosecution Insights
10 pending office actions • 7 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (10%) |
| §103 only | 2 (20%) |
| §102 only | 3 (30%) |
| §112 only | 3 (30%) |
| No statute on record | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| BOWLES, DAVID PAUL | 1 | 75.0% | +17.5% |
| GILL, RACHEL B | 1 | 65.6% | +27.7% |
| EMCH, GREGORY S | 1 | 49.0% | +44.3% |
| SINGH, ANOOP KUMAR | 1 | 42.8% | +67.6% |
| MOORE, JOHN DAVID | 1 | 70.5% | +18.1% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +69.0% |
| TRAN, KHOA NHAT | 1 | 35.4% | +66.3% |
| JOHANNSEN, DIANA B | 1 | 53.2% | +41.1% |
| DIBRINO, MARIANNE | 1 | 43.3% | +41.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17274126 | BIOMARKERS FOR CANCER THERAPY | JOHANNSEN, DIANA B | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16938214 | IMMUNORECEPTOR MODULATION FOR TREATING CANCER AND VIRAL INFECTIONS | DIBRINO, MARIANNE | 100d overdue |
| 18025763 | Methods of Determining Immune Response | EMCH, GREGORY S | 66d overdue |
| 17581617 | IMMUNOTHERAPY FOR POLYOMAVIRUSES | DABKOWSKI, ERINNE R | 59d overdue |
| 17440081 | CARDIOMYOCYTE PROLIFERATION | TRAN, KHOA NHAT | 37d overdue |
| 18273200 | NOVEL BICYCLIC PEPTIDES | BOWLES, DAVID PAUL | 25d overdue |
| 17782544 | DEFECTIVE INTERFERING PARTICLES | MOORE, JOHN DAVID | 7d |
| 18393160 | HUMAN HERPESVIRUS IMMUNOTHERAPY | BLUMEL, BENJAMIN P | 26d |
| 17913937 | COMPOSITIONS AND METHODS FOR TARGETING HPV-INFECTED CELLS | SINGH, ANOOP KUMAR | 26d |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1654 | 2 |
| 1632 | 2 |
| 1678 | 1 |
| 1638 | 1 |
| 1682 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18393160 | HUMAN HERPESVIRUS IMMUNOTHERAPY | BLUMEL, BENJAMIN P | 1671 | §103 | Final Rejection | 26d | Pending | Dec 21, 2023 |
| 18273200 | NOVEL BICYCLIC PEPTIDES | BOWLES, DAVID PAUL | 1654 | §112 | Non-Final OA | 25d overdue | Pending | Jul 19, 2023 |
| 18030892 | HERPESVIRUS POLYEPITOPE VACCINES | GILL, RACHEL B | 1671 | Other | Non-Final OA | 34d | Pending | Apr 07, 2023 |
| 18025763 | Methods of Determining Immune Response | EMCH, GREGORY S | 1678 | §102 | Non-Final OA | 66d overdue | Pending | Mar 10, 2023 |
| 17913937 | COMPOSITIONS AND METHODS FOR TARGETING HPV-INFECTED CELLS | SINGH, ANOOP KUMAR | 1632 | §102 | Non-Final OA | 26d | Pending | Sep 23, 2022 |
| 17782544 | DEFECTIVE INTERFERING PARTICLES | MOORE, JOHN DAVID | 1638 | §102 | Final Rejection | 7d | Pending | Jun 03, 2022 |
| 17581617 | IMMUNOTHERAPY FOR POLYOMAVIRUSES | DABKOWSKI, ERINNE R | 1654 | §103 | Final Rejection | 59d overdue | Pending | Jan 21, 2022 |
| 17440081 | CARDIOMYOCYTE PROLIFERATION | TRAN, KHOA NHAT | 1632 | §112 | Final Rejection | 37d overdue | Pending | Sep 16, 2021 |
| 17274126 | BIOMARKERS FOR CANCER THERAPY | JOHANNSEN, DIANA B | 1682 | §101 | Non-Final OA | 33d | Pending | Mar 05, 2021 |
| 16938214 | IMMUNORECEPTOR MODULATION FOR TREATING CANCER AND VIRAL INFECTIONS | DIBRINO, MARIANNE | 1641 | §112 | Final Rejection | 100d overdue | Pending | Jul 24, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial